Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Longitudinal analysis of the utility of liver biochemistry in hospitalised COVID-19 patients as prognostic markers

View ORCID ProfileTingyan Wang, View ORCID ProfileDavid A Smith, View ORCID ProfileCori Campbell, View ORCID ProfileSteve Harris, View ORCID ProfileHizni Salih, View ORCID ProfileKinga A Várnai, View ORCID ProfileKerrie Woods, Theresa Noble, Oliver Freeman, Zuzana Moysova, View ORCID ProfileThomas Marjot, View ORCID ProfileGwilym J Webb, View ORCID ProfileJim Davies, View ORCID ProfileEleanor Barnes, View ORCID ProfilePhilippa C Matthews
doi: https://doi.org/10.1101/2020.09.15.20194985
Tingyan Wang
1NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford
2Nuffield Department of Medicine, University of Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tingyan Wang
David A Smith
1NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford
3Oxford University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David A Smith
Cori Campbell
1NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford
2Nuffield Department of Medicine, University of Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cori Campbell
Steve Harris
1NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford
4Department of Computer Science, University of Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steve Harris
Hizni Salih
1NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hizni Salih
Kinga A Várnai
1NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford
3Oxford University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kinga A Várnai
Kerrie Woods
1NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford
3Oxford University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kerrie Woods
Theresa Noble
1NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford
3Oxford University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Freeman
1NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zuzana Moysova
1NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford
3Oxford University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Marjot
5Oxford Liver Unit, Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford University Hospitals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thomas Marjot
Gwilym J Webb
6Cambridge Liver Unit, Addenbrooke’s Hospital, Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gwilym J Webb
Jim Davies
1NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford
4Department of Computer Science, University of Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jim Davies
Eleanor Barnes
2Nuffield Department of Medicine, University of Oxford
3Oxford University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eleanor Barnes
  • For correspondence: ellie.barnes@ndm.ox.ac.uk
Philippa C Matthews
3Oxford University Hospitals NHS Foundation Trust
7Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philippa C Matthews
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background COVID-19, the clinical syndrome caused by infection with SARS-CoV-2, has been associated with deranged liver biochemistry in studies from China, Italy and the USA. However, the clinical utility of liver biochemistry as a prognostic marker of outcome for COVID-19 is currently debated.

Methods We extracted routinely collected clinical data from a large teaching hospital in the UK, matching 585 hospitalised SARS-CoV-2 RT-PCR-positive patients to 1165 hospitalised SARS-CoV-2 RT-PCR-negative patients for age, gender, ethnicity and pre-existing comorbidities. Liver biochemistry was compared between groups over time to determine whether derangement was associated with outcome.

Results 26.8% (157/585) of COVID-19 patients died, compared to 11.9% (139/1165) in the non-COVID-19 group (p<0.001). At presentation, a significantly higher proportion of the COVID-19 group had elevated alanine aminotransferase (20.7% vs. 14.6%, p=0.004) and hypoalbuminaemia (58.7% vs. 35.0%, p<0.001), compared to the non-COVID-19 group. Within the COVID-19 group, those with hypoalbuminaemia at presentation had 1.83-fold increased hazards of death compared to those with normal albumin (adjusted hazard ratio [HR] 1.83, 95% CI 1.25-2.67), whilst the hazard of death was ~4-fold higher in those aged ≥75 years (adjusted HR 3.96, 95% CI 2.59-6.04) and ~3-fold higher in those with pre-existing liver disease (adjusted HR 3.37, 95% CI 1.58-7.16). In the COVID-19 group, alkaline phosphatase increased (R=0.192, p<0.0001) and albumin declined (R=-0.123, p=0.0004) over time in patients who died. We did not find a significant association between other liver biochemistry and death.

Conclusion In this UK population, liver biochemistry is commonly deranged in patients with COVID-19 but only baseline low albumin and a rising alkaline phosphatase over time are prognostic markers for death.

Key Points

  • Age ≥ 75 years and low albumin at the time of a positive SARS-CoV-2 RT-PCR test can predict poor clinical outcome in COVID-19 patients.

  • Liver biochemistry is more likely to be abnormal in patients with COVID-19 than in patients without COVID-19.

  • Patients with COVID-19 who died showed a greater decline in albumin and a greater increase in alkaline phosphatase over time, compared to those who survived.

  • Patients with pre-existing liver disease and COVID-19 had an increased mortality.

Lay Summary We used routinely collected hospital data from a large UK teaching hospital to compare liver biochemistry (markers of liver inflammation or damage) between 585 patients with COVID-19 and 1165 patients of the same age and sex admitted to hospital but without COVID-19. Patients with COVID-19 were more likely to die than those without COVID-19, and deaths were significantly higher in those aged ≥75 years. We found that patients with COVID-19 were more likely to have abnormal liver biochemistry. Low albumin (a blood protein) at the time of being diagnosed with COVID-19 was associated with an increased chance of death.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work has been supported by the NIHR Biomedical Research Centre (BRC) at Oxford and funded by the NIHR Health Informatics Collaborative (HIC). C.C reports funding from GlaxoSmithKline. T.M has received financial support from the European Association for the Study of the Liver (EASL). G.J.W has received financial support from the European Association for the Study of the Liver (EASL) for COVID-Hep.net. E.B is an NIHR Senior Investigator. The views expressed in this article are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health.
P.C.M is funded by the Wellcome Trust and holds an NIHR Senior Fellowship award.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All of the data used for this study were provided in anonymised form by OUH NHS Foundation Trust, with the prior approval of the Trust Information Governance Team, following the satisfactory completion of a Data Protection Impact Assessment. The management of the dataset is governed by the NIHR HIC Data Sharing Framework. Research Ethics Committee approval was obtained for the database and associated activity: IRAS ID 174658; REC reference 15/SC/0523.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

N/A

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 18, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Longitudinal analysis of the utility of liver biochemistry in hospitalised COVID-19 patients as prognostic markers
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Longitudinal analysis of the utility of liver biochemistry in hospitalised COVID-19 patients as prognostic markers
Tingyan Wang, David A Smith, Cori Campbell, Steve Harris, Hizni Salih, Kinga A Várnai, Kerrie Woods, Theresa Noble, Oliver Freeman, Zuzana Moysova, Thomas Marjot, Gwilym J Webb, Jim Davies, Eleanor Barnes, Philippa C Matthews
medRxiv 2020.09.15.20194985; doi: https://doi.org/10.1101/2020.09.15.20194985
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Longitudinal analysis of the utility of liver biochemistry in hospitalised COVID-19 patients as prognostic markers
Tingyan Wang, David A Smith, Cori Campbell, Steve Harris, Hizni Salih, Kinga A Várnai, Kerrie Woods, Theresa Noble, Oliver Freeman, Zuzana Moysova, Thomas Marjot, Gwilym J Webb, Jim Davies, Eleanor Barnes, Philippa C Matthews
medRxiv 2020.09.15.20194985; doi: https://doi.org/10.1101/2020.09.15.20194985

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1110)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (275)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
  • Epidemiology (9796)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2327)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1567)
  • Health Policy (737)
  • Health Systems and Quality Improvement (608)
  • Hematology (238)
  • HIV/AIDS (508)
  • Infectious Diseases (except HIV/AIDS) (11669)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2154)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (519)
  • Oncology (1185)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (314)
  • Pediatrics (699)
  • Pharmacology and Therapeutics (303)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2195)
  • Public and Global Health (4685)
  • Radiology and Imaging (786)
  • Rehabilitation Medicine and Physical Therapy (458)
  • Respiratory Medicine (625)
  • Rheumatology (276)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (212)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)